<DOC>
	<DOCNO>NCT00033527</DOCNO>
	<brief_summary>RATIONALE : INS316 may produce good sputum sample laboratory analysis may provide less invasive method diagnose lung cancer . PURPOSE : Randomized diagnostic trial compare effectiveness INS316 saline sputum collection diagnose lung cancer patient suspect lung cancer .</brief_summary>
	<brief_title>INS316 Compared With Saline Sputum Collection Diagnosing Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare number lung cancer diagnosis obtain cytological evaluation sputum expectorate inhalation INS316 versus normal saline adjunct spontaneous expectoration sputum patient suspect lung cancer . - Compare relative sensitivity sputum cytology diagnosis primary lung cancer use method sputum collection patient . - Compare amount sputum collect patient use method . - Correlate number macrophage sputum predictive likelihood obtain positive diagnosis sputum cytology patient . - Determine whether specificity sputum cytology adversely affected induction INS316 patient . OUTLINE : This randomize , double-blind , placebo-controlled , parallel , multicenter study . Patients stratify accord tumor size location visualize chest radiography , CT scan , positron-emission tomography scan ( peripheral tumor ( distal subsegmental bronchus ) great 2 cm diameter vs peripheral tumor great 2 cm diameter vs central tumor great 2 cm diameter vs central tumor great 2 cm diameter ) . Patients randomize one two arm . Prior dose sputum induction adjunct , patient expectorate sputum spontaneously . - Arm I : Patients receive single dose INS316 inhalation . - Arm II : Patients receive single dose placebo ( normal saline ) inhalation . In arm , patient expectorate sputum dosing , immediately dose , within 15 , 30 , 60 minute dose . Patients follow day 1 dosing , 8 week diagnosis make , 3 month diagnosis malignant . PROJECTED ACCRUAL : Approximately 800 patient ( 600 confirm diagnosis malignancy make ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Suspected primary lung cancer chest radiography , CT scan , positronemission tomography scan symptom , risk profile , history suggestive malignancy No prior confirm diagnosis current suspicious lung tumor Expected histological cytological confirmation within 8 week study completion No prior treatment current suspicious tumor unless current lesion recurrence tumor ( location ) prior treatment receive least 180 day prior study FEV_1 least 40 % predict PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent comorbid condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics Surgery : At least 4 day since prior pulmonary fine needle aspiration biopsy No concurrent mediastinoscopy thoracotomy Other : At least 4 day since prior bronchoscopic examination At least 3 day since prior sputum induction At least 30 day since prior investigational drug ( include INS316 ) experimental therapy No concurrent medication would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>small cell lung cancer</keyword>
</DOC>